This interview features: Sebastian Giehring, CEO, PAIA. PAIA is presenting the world´s first assay for assessing mispairing of complex biotherapeutics based on charge differences. Mispairing is a huge challenge in the assembly of bispecific antibodies. It refers to the situation where chains from different monoclonal antibodies incorrectly pair with each other, producing process related impurities that have to be monotore during the bioprocess development. PAIA are showing data from one of the first bispecific biosimilars and illustrate the assay principle…

This presentation features: Milla Neffling, PhD, Market Segment Manager, 908 Devices. Faster development cycles, intensified processes, and automation of process control are key-initiatives in biotherapeutics manufacturing. However, offline analytics requiring manual intervention are commonly used to monitor critical and time-sensitive process parameters. We describe a new automated approach for optimal growth and production, leveraging sensitive, online (sample-free) monitoring of glucose and lactate with automated feed control, and its impact on growth/viability, lower metabolite, and improved PQA.   Fill out the…

This interview features: William Barrett, PhD, Product Specialist, WL Gore & Associates. William Barrett, PhD is a product specialist with WL Gore & Associates. He has over 20 years combined experience in biotechnology, chromatography, and the medical device industries. Most recently at WL Gore, Bill’s focused on affinity purification chromatography. Previously, Bill worked at Agilent on affinity depletion devices used in biomarker discovery and proteomics. He received a PhD in biochemistry from the University of Illinois and completed his fellowship…

This interview features: Amy Bennett, Manager of Virology Scientific Support, Charles River Laboratories. Amy joined Charles River in 2010 as technician within the Virology Department and is now manager of Virology Scientific Support. She currently oversees development within the department as well as technical transfers. Amy has worked on the development and implementation of safety assays for various gene therapy vectors including adenovirus, adeno-associated virus, and lentivirus. She has a master’s degree in biology from West Chester University.